Trade Harvard Bioscience - HBIO CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.12
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.022207 %(-$4.44)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02221%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000015 %(-$0.00)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.00002%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 100
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.022207 %
  (-$4.44)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000015 %
  (-$0.00)

Key Stats

• Prev. Close: 8.0099
• Open: 7.8999
• 1-Year Change: 1700.34%
• Day's Range: 7.8999 - 7.95

Trade Harvard Bioscience - HBIO

About Harvard Bioscience, Inc.

Harvard Bioscience, Inc. is a developer, manufacturer, and seller of technologies, products and services that enable fundamental research, discovery, and preclinical testing for drug development. The Company provides products that support research in six different classes of laboratory use, including molecular, cellular, tissue, organ, organisms, and clinical. The Company primarily sells its products under several brand names, including Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS. The Company’s customers include pharmaceutical and biotechnology companies, as well as contract research organizations, academic labs, and government researchers.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Harvard Bioscience, Inc. revenues increased 16% to $118.9M. Net loss decreased 96% to $288K. Revenues reflect United States segment increase of 18% to $49.8M, Europe segment increase of 19% to $35.8M. Lower net loss reflects Interest expense decrease of 68% to $1.5M (expense), G/L on early Exting of lease relat debt decrease from $1.9M (expense) to $0K.

Equity composition

Common Stock $.01 Par, 12/10, 80M auth., 36,057,974 issd., less 7,745,507 shs. in Treas. @ 10.7M. Insiders & Strategic holders own 13.56%. IPO: 12/7/2000, 6,420,000 shs. @$8 by Thomas Weisel Partners LLC. *NOTE: 10/02, Company acquired Genomic Solutions, Inc. @ 0.1017 shares and $0.286 in cash (3,178,857 shares issd.).